Enzo Biochem Cash on Hand 2010-2022 | ENZ

Enzo Biochem cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Enzo Biochem Annual Cash on Hand
(Millions of US $)
2021 $44
2020 $48
2019 $60
2018 $60
2017 $64
2016 $68
2015 $18
2014 $17
2013 $9
2012 $15
2011 $24
2010 $34
2009 $50
Enzo Biochem Quarterly Cash on Hand
(Millions of US $)
2022-04-30 $31
2022-01-31 $34
2021-10-31 $36
2021-07-31 $44
2021-04-30 $45
2021-01-31 $45
2020-10-31 $46
2020-07-31 $48
2020-04-30 $54
2020-01-31 $52
2019-10-31 $57
2019-07-31 $60
2019-04-30 $64
2019-01-31 $42
2018-10-31 $53
2018-07-31 $60
2018-04-30 $63
2018-01-31 $64
2017-10-31 $67
2017-07-31 $64
2017-04-30 $63
2017-01-31 $62
2016-10-31 $67
2016-07-31 $68
2016-04-30 $32
2016-01-31 $37
2015-10-31 $31
2015-07-31 $18
2015-04-30 $14
2015-01-31 $15
2014-10-31 $17
2014-07-31 $17
2014-04-30 $15
2014-01-31 $8
2013-10-31 $7
2013-07-31 $9
2013-04-30 $6
2013-01-31 $10
2012-10-31 $13
2012-07-31 $15
2012-04-30 $15
2012-01-31 $19
2011-10-31 $21
2011-07-31 $24
2011-04-30 $28
2011-01-31 $31
2010-10-31 $32
2010-07-31 $34
2010-04-30 $34
2010-01-31 $44
2009-10-31 $46
2009-07-31 $50
2009-04-30 $55
2009-01-31 $73
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.104B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00